Conmed Corporation (CNMD) Holder Champlain Investment Partners LLC Has Decreased Its Stake

CONMED Corporation (NASDAQ:CNMD) LogoInvestors sentiment decreased to 1.18 in Q2 2019. Its down 0.60, from 1.78 in 2019Q1. It dived, as 20 investors sold CNMD shares while 64 reduced holdings. 32 funds opened positions while 67 raised stakes. 30.45 million shares or 20.13% less from 38.12 million shares in 2019Q1 were reported. 371,327 were reported by Loomis Sayles And Limited Partnership. Carroll Fin Associate Inc stated it has 0% in CONMED Corporation (NASDAQ:CNMD). Prudential Financial Incorporated has invested 0.02% in CONMED Corporation (NASDAQ:CNMD). Parametric Port Ltd has invested 0.01% in CONMED Corporation (NASDAQ:CNMD). Fifth Third Bancorp holds 0% or 4,316 shares. Huber Cap Management Lc reported 44,882 shares or 0.46% of all its holdings. Virginia Retirement Et Al stated it has 0.03% of its portfolio in CONMED Corporation (NASDAQ:CNMD). Us Commercial Bank De accumulated 1,136 shares. Thrivent Financial For Lutherans reported 0.01% stake. Globeflex Capital Lp holds 0.28% of its portfolio in CONMED Corporation (NASDAQ:CNMD) for 15,800 shares. Meeder Asset has 492 shares for 0% of their portfolio. Arizona State Retirement System reported 0.04% in CONMED Corporation (NASDAQ:CNMD). Metropolitan Life reported 0.01% of its portfolio in CONMED Corporation (NASDAQ:CNMD). National Bank & Trust Of Mellon has 0.01% invested in CONMED Corporation (NASDAQ:CNMD). Principal Grp Inc Inc invested 0.05% of its portfolio in CONMED Corporation (NASDAQ:CNMD).

Champlain Investment Partners Llc decreased its stake in Conmed Corporation (CNMD) by 5% based on its latest 2019Q2 regulatory filing with the SEC. Champlain Investment Partners Llc sold 87,336 shares as the company’s stock rose 9.52% . The institutional investor held 1.66 million shares of the electromedical & electrotherapeutic apparatus company at the end of 2019Q2, valued at $87.11 million, down from 1.75 million at the end of the previous reported quarter. Champlain Investment Partners Llc who had been investing in Conmed Corporation for a number of months, seems to be less bullish one the $2.69B market cap company. The stock increased 1.53% or $1.43 during the last trading session, reaching $95.02. About 150,821 shares traded. CONMED Corporation (NASDAQ:CNMD) has risen 19.51% since October 12, 2018 and is uptrending. It has outperformed by 19.51% the S&P500.

Champlain Investment Partners Llc, which manages about $6.04B and $8.47B US Long portfolio, upped its stake in Palo Alto Networks Inc. (NYSE:PANW) by 47,285 shares to 772,910 shares, valued at $111.38 million in 2019Q2, according to the filing. It also increased its holding in German American Bancorp Inc. (NASDAQ:GABC) by 97,238 shares in the quarter, for a total of 900,125 shares, and has risen its stake in Stericycle Inc. (NASDAQ:SRCL).

Analysts await CONMED Corporation (NASDAQ:CNMD) to report earnings on November, 7. They expect $0.56 EPS, up 21.74 % or $0.10 from last year’s $0.46 per share. CNMD’s profit will be $15.84 million for 42.42 P/E if the $0.56 EPS becomes a reality. After $0.56 actual EPS reported by CONMED Corporation for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

More notable recent CONMED Corporation (NASDAQ:CNMD) news were published by: which released: “Dirk Kuyper to Step Down from CONMED Corporation Board of Directors Effective August 1, 2019 – Business Wire” on June 18, 2019, also with their article: “CONMED Corporation 2018 Q3 – Results – Earnings Call Slides – Seeking Alpha” published on November 04, 2018, published: “Masimo (MASI) Boosts O3 Platform With Three New Indices – Nasdaq” on September 10, 2019. More interesting news about CONMED Corporation (NASDAQ:CNMD) were released by: and their article: “CONMED (CNMD) Q2 Earnings and Revenues Surpass Estimates – Yahoo Finance” published on August 01, 2019 as well as‘s news article titled: “AMN Healthcare (AMN) Q4 Earnings Top, Revenues Lag Estimates – Nasdaq” with publication date: March 08, 2019.

CONMED Corporation (NASDAQ:CNMD) Ratings Coverage

Among 3 analysts covering Conmed (NASDAQ:CNMD), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Conmed has $11000 highest and $92 lowest target. $100.33’s average target is 5.59% above currents $95.02 stock price. Conmed had 5 analyst reports since April 15, 2019 according to SRatingsIntel. The firm has “Buy” rating by Stifel Nicolaus given on Thursday, August 1. The stock has “Overweight” rating by Barclays Capital on Monday, April 15. The rating was upgraded by Piper Jaffray to “Overweight” on Thursday, August 22.

CONMED Corporation (NASDAQ:CNMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.